October 14, 2021 -- IsoPlexis completed an initial public offering (IPO) on October 12, closing with $125 million on the sale of approximately 8.3 million shares at $15 per share.
IsoPlexis develops single-cell proteomics systems that reveal unique biological activity in small subsets of cells. This technology allows researchers to connect more directly to in vivo biology and develop more precise and personalized therapies, the company said.
The company's common stock began trading on the Nasdaq Global Select Market on October 8 under the ticker symbol ISO. Shares were offered by IsoPlexis, while Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are acting as lead book-running managers for the offering.
Copyright © 2021 scienceboard.net